Management is buying the same thing twice: proven demand from one place is being replicated into identified new places r
The model's full reasoning — Q3 2016 call → NOWe need answer only YES or NO. Need analyze transcript. Need determine if management describes currently in middle of copying a part of own business already working into additional places where same demand already visible. Need all three: proven instance works, copies being stood up now, demand already identified at destination, and replication large relative to company, results reflect original. Let's parse transcript. Company Fate Therapeutics. Programs: ProTmune (hematopoietic cell graft) clinical trial Phase 1/2 PROTECT. FATE-NK100 natural killer cell program IND filed, clinical testing expected early 2017. ToleraCyte pre-IND. iPSC platform. Need see if any "copying a part of business already working" into additional places. Maybe clinical trial sites? Seven U.S. clinical sites open for enrollment in Phase 1/2 PROTECT trial. They are expanding sites for Phase 2 including UK. But is that copying a proven instance? No, product not proven yet, trial ongoing. No. Maybe FATE-NK100: "While conventional NK cell therapies have shown promise in clinic... FATE-NK100 is enriched..." Not proven. IND filed, first in human testing underway. No. Maybe "we formed multiyear partnership with Memorial Sloan-Kettering... leapfrogging current patient specific approach... research activities..." Not. Maybe "ToleraCyte" pre-IND. No. Question asks "does management describe company as CURRENTLY IN THE MIDDLE OF COPYING A PART OF ITS OWN BUSINESS THAT IS ALREADY WORKING INTO ADDITIONAL PLACES WHERE THE SAME DEMAND IS ALREADY VISIBLE" — likely no. They are clinical-stage biotech, no commercial product. No proven instance. No copies. So answer NO. Need be careful: Could be "clinical sites" as instances? They are opening multiple sites for trial. But not proven business, not demand. No. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| VSEC | VSE Corporation | Q3 2022 | 2022-10-28 | B+ |
| FSLR | First Solar, Inc. | Q3 2022 | 2022-10-28 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| TPIC | TPI Composites, Inc. | Q3 2018 | 2018-11-11 | C |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOLD | Amicus Therapeutics, Inc. | Q1 2018 | 2018-05-08 | C+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| VSAT | Viasat, Inc. | Q4 2017 | 2017-05-23 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GDS · Q2 2021 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a clear, present-tense replication of their proven China-based data center platform into new markets (Hong Kong, Macau, Southeast Asia) where demand is already visible and committed. William Huang explicitly references the “proven” China edge-of-town model (land-and-expand MOUs, 500 000 sqm secured pipeline, hyperscale orders already landed) and states they are “currently developing two purpose-built data centers” in Hong Kong (HK1/HK2) with most capacity “already allocated to strategic customers pending contracts,” plus a new building (HK4) under agreement and a heads-of-agreement for HK3, creating “nearly 80 megawatts of purpose-built capacity through to 2027.” For Macau they have a JV to acquire brownfield sites for redevelopment (20 MW).
FOLD · Q1 2018 → YESThe question is about whether management describes the company as currently copying a proven part of its business into additional places where demand is already visible. YES The transcript shows management describing Galafold as a proven commercial offering (Q1 revenue $16.7M, 300% YoY growth, hundreds of patients, high compliance, 7 approvals, 18 countries with pricing/reimbursement) that is now being replicated into additional markets.
TPIC · Q3 2018 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a proven manufacturing operation (existing dedicated lines and plants in the U.S.